Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer

Abstract

Many genes associated with CpG islands undergo de novo methylation in cancer. Studies have suggested that the pattern of this modification may be partially determined by an instructive mechanism that recognizes specifically marked regions of the genome1. Using chromatin immunoprecipitation analysis, here we show that genes methylated in cancer cells are specifically packaged with nucleosomes containing histone H3 trimethylated on Lys27. This chromatin mark is established on these unmethylated CpG island genes early in development and then maintained in differentiated cell types by the presence of an EZH2-containing Polycomb complex2,3. In cancer cells4, as opposed to normal cells, the presence of this complex brings about the recruitment of DNA methyl transferases, leading to de novo methylation. These results suggest that tumor-specific targeting of de novo methylation is pre-programmed by an established epigenetic system that normally has a role in marking embryonic genes for repression2.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Caco-2 methylated genes are packaged with trimethylated H3K27.
Figure 2: Genes methylated in cancer are marked by Polycomb components.
Figure 3: Targeted genes are associated with DNMTs in Caco-2 cells.
Figure 4: Tumor suppressor genes.

Similar content being viewed by others

References

  1. Keshet, I. et al. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat. Genet. 38, 149–153 (2006).

    Article  CAS  PubMed  Google Scholar 

  2. Lee, T.I. et al. Control of developmental regulators by polycomb in human embryonic stem cells. Cell 125, 301–313 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Bracken, A.P., Dietrich, N., Pasini, D., Hansen, K.H. & Helin, K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 20, 1123–1136 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Vire, E. et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439, 871–874 (2005).

    Article  PubMed  Google Scholar 

  5. Brandeis, M. et al. Sp1 elements protect a CpG island from de novo methylation. Nature 371, 435–438 (1994).

    Article  CAS  PubMed  Google Scholar 

  6. Gidekel, S. & Bergman, Y. A unique developmental pattern of Oct-3/4 DNA methylation is controlled by a cis-demodification element. J. Biol. Chem. 277, 34521–34530 (2002).

    Article  CAS  PubMed  Google Scholar 

  7. Lock, L.F., Takagi, N. & Martin, G.R. Methylation of the HPRT gene on the inactive X occurs after chromosome inactivation. Cell 48, 39–46 (1987).

    Article  CAS  PubMed  Google Scholar 

  8. Feldman, N. et al. G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis. Nat. Cell Biol. 8, 188–194 (2006).

    Article  CAS  PubMed  Google Scholar 

  9. Plath, K. et al. Role of histone H3 lysine 27 methylation in X inactivation. Science 300, 131–135 (2003).

    Article  CAS  PubMed  Google Scholar 

  10. Silva, J. et al. Establishment of histone H3 methylation on the inactive X chromosome requires transient recruitment of Eed-Enx1 polycomb group complexes. Dev. Cell 4, 481–495 (2003).

    Article  CAS  PubMed  Google Scholar 

  11. Cao, R. & Zhang, Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr. Opin. Genet. Dev. 14, 155–164 (2004).

    Article  CAS  PubMed  Google Scholar 

  12. Squazzo, S.L. et al. Suz12 binds to silenced regions of the genome in a cell-type-specific manner. Genome Res. 16, 890–900 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Zardo, G. et al. Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors. Nat. Genet. 32, 453–458 (2002).

    Article  CAS  PubMed  Google Scholar 

  14. Rush, L.J. & Plass, C. Restriction landmark genomic scanning for DNA methylation in cancer: past, present, and future applications. Anal. Biochem. 307, 191–201 (2002).

    Article  CAS  PubMed  Google Scholar 

  15. Alaminos, M., Davalos, V., Cheung, N.K., Gerald, W.L. & Esteller, M. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J. Natl. Cancer Inst. 96, 1208–1219 (2004).

    Article  CAS  PubMed  Google Scholar 

  16. Bestor, T.H. The DNA methyltransferases of mammals. Hum. Mol. Genet. 9, 2395–2402 (2000).

    Article  CAS  PubMed  Google Scholar 

  17. Di Croce, L. et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295, 1079–1082 (2002).

    Article  CAS  PubMed  Google Scholar 

  18. Jones, P.A. & Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3, 415–428 (2002).

    Article  CAS  PubMed  Google Scholar 

  19. Wong, D.J., Foster, S.A., Galloway, D.A. & Reid, B.J. Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M0 growth arrest. Mol. Cell. Biol. 19, 5642–5651 (1999).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Esteller, M. et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum. Mol. Genet. 10, 3001–3007 (2001).

    Article  CAS  PubMed  Google Scholar 

  21. Boyer, L.A. et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 441, 349–353 (2006).

    Article  CAS  PubMed  Google Scholar 

  22. McGarvey, K.M. et al. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res. 66, 3541–3549 (2006).

    Article  CAS  PubMed  Google Scholar 

  23. De Marzo, A.M. et al. Abnormal regulation of DNA methyltransferase expression during colorectal carcinogenesis. Cancer Res. 59, 3855–3860 (1999).

    CAS  PubMed  Google Scholar 

  24. Robertson, K.D. et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 27, 2291–2298 (1999).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Feltus, F.A., Lee, E.K., Costello, J.F., Plass, C. & Vertino, P.M. Predicting aberrant CpG island methylation. Proc. Natl. Acad. Sci. USA 100, 12253–12258 (2003).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624–629 (2002).

    Article  CAS  PubMed  Google Scholar 

  27. Bracken, A.P. et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 22, 5323–5335 (2003).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Nguyen, C. et al. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J. Natl. Cancer Inst. 93, 1465–1472 (2001).

    Article  CAS  PubMed  Google Scholar 

  29. Reubinoff, B.E., Pera, M.F., Fong, C.Y., Trounson, A. & Bongso, A. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat. Biotechnol. 18, 399–404 (2000).

    Article  CAS  PubMed  Google Scholar 

  30. Cao, R. & Zhang, Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol. Cell 15, 57–67 (2004).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Y. Zhang for antibody to trimethylated H3K27. This work was supported by grants from the US National Institutes of Health, the Israel Cancer Research Fund, the Rosetrees Trust, Lewis Sanders, the Prostate Cancer Foundation and both Philip Morris USA Inc. and Philip Morris International (H.C. and R.S.).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Howard Cedar.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Fig. 1

Methylated genes are packaged with trimethylated H3K27 in Caco-2. (PDF 23 kb)

Supplementary Fig. 2

Histone modification of genes methylated in cancer. (PDF 99 kb)

Supplementary Table 1

Bioinformatic confirmation of trimethylated H3K27 ChIP. (PDF 77 kb)

Supplementary Table 2

General association of Polycomb components with genes methylated in cancer. (PDF 49 kb)

Supplementary Table 3

Association of Polycomb components with genes methylated in cancer. (PDF 51 kb)

Supplementary Table 4

Genes marked with Polycomb reported to be hypermethylated in cancer. (PDF 65 kb)

Supplementary Table 5

PCR primer sequences. (PDF 31 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schlesinger, Y., Straussman, R., Keshet, I. et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39, 232–236 (2007). https://doi.org/10.1038/ng1950

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng1950

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing